Home / About us / Leadership / John Stapleton
John Stapleton
Senior IT Manager
John yields over three decades of experience driving technology strategy and digital transformation. Prior to AGADA, John started off as a Y2K programmer for a large insurance firm before branching out to work as a hardware technician, web designer, and project manager. John subsequently transitioned to IT management and has gained experience leading IT departments across various industries.
John spearheads AGADA’s IT strategy, keeping the company’s digital systems secure and scalable while managing cybersecurity, network infrastructure, software systems, and data storage. John also implements new technology to support laboratory operations and maintain compliance with data privacy regulations.
Get in touch
To learn how AGADA Biosciences could support your program, get in touch with our team and start the conversation.
How we work
We bring an agile, collaborative and responsive approach to every engagement, shaping our support around the needs of your program rather than a rigid process. Whether you engage us at a single stage or across multiple points in development, we work to de-risk programs, protect data integrity and help your teams progress with confidence.
1
Refined for your program:
We shape our approach around the needs of each program, not the other way around.
2
Direct access to senior experts:
Our lean model keeps scientific expertise close to the work and communication clear.
3
Built to de-risk progress:
We help you de-risk development through rigorous science and practical support.
4
Protecting data integrity:
Our work is designed to support reliable outputs and maintain confidence in the data.
Why AGADA?
We bring dedicated expertise to programs where there is little room for error, providing the scientific support, responsiveness and program fit that help rare disease teams move forward with clarity.
Decade of specialization:
Founded in 2013 as a spinout from Children’s National Medical Center to provide specialist scientific support for rare disease drug development.
Consistent audit success:
We successfully pass an average of five sponsor audits annually to support clinical trials across multiple phases.
Historical benchmarking:
We leverage archival data from over 100 trials in mouse models of muscular dystrophy to accurately power your efficacy studies.
Dedicated scale:
We operate with a team of approximately 50 employees, entirely focused on executing complex rare disease programs.
Meet more of the leadership team
